Ignite Creation Date:
2025-12-25 @ 4:59 AM
Ignite Modification Date:
2026-03-14 @ 8:01 AM
Study NCT ID:
NCT03755518
Status:
TERMINATED
Last Update Posted:
2024-12-12
First Post:
2018-11-08
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Sponsor:
Celgene
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-03-27
Start Date Type:
ACTUAL
Primary Completion Date:
2021-11-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-11-08
Completion Date Type:
ACTUAL
First Submit Date:
2018-11-08
First Submit QC Date:
None
Study First Post Date:
2018-11-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-11-22
Results First Submit QC Date:
None
Results First Post Date:
2023-03-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-11
Last Update Post Date:
2024-12-12
Last Update Post Date Type:
ACTUAL